170 results on '"Meyerhardt, J"'
Search Results
2. Alliance A022101: A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer – Evaluating Radiation, Ablation and Surgery (ERASur)
3. A Single-Institution Experience of Acute Neuropathic Lumbosacral Pain in Patients Treated with Short Course Hypofractionated Radiotherapy in Locally Advanced Rectal Cancer
4. Histopathology images predict multi-omics aberrations and prognoses in colorectal cancer patients
5. Bayesian risk prediction model for colorectal cancer mortality through integration of clinicopathologic and genomic data
6. Inverse relationship between Fusobacterium nucleatum amount and tumor CD274 (PD-L1) expression in colorectal carcinoma
7. Radiation Therapy (RT) Quality Assurance (QA) Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Pancreas (PDAC)
8. 317MO Efficacy of oxaliplatin-based adjuvant chemotherapy in older patients with stage III colon cancer: An ACCENT/IDEA pooled analysis of 12 trials
9. LBA26 SOLARIS (Alliance A021703): A multicenter double-blind phase III randomized clinical trial (RCT) of vitamin D (VitD) combined with standard chemotherapy plus bevacizumab (bev) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC)
10. 1141O Cabozantinib versus placebo for advanced neuroendocrine tumors (NET) after progression on prior therapy (CABINET Trial/Alliance A021602): Updated results including progression free-survival (PFS) by blinded independent central review (BICR) and subgroup analyses
11. SO-38 Clinical efficacy and single-cell analysis of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
12. Spatial organization and prognostic significance of NK and NKT-like cells via multimarker analysis of the colorectal cancer microenvironment
13. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology
14. Association of Fusobacterium nucleatum with specific T-cell subsets in the colorectal carcinoma microenvironment
15. 597P Surgical quality for patients (pts) treated with neoadjuvant chemotherapy vs chemoradiation for locally advanced rectal cancer (LARC): PROSPECT (NCCTG N1048, alliance)
16. Tumor long interspersed nucleotide element-1 (LINE-1) hypomethylation in relation to age of colorectal cancer diagnosis and prognosis
17. The prognostic role of macrophage polarization in the colorectal cancer microenvironment
18. Association of PIK3CA mutation and PTEN loss with expression of CD274 (PD-L1) in colorectal carcinoma
19. Prognostic significance of myeloid immune cells and their spatial distribution in the colorectal cancer microenvironment
20. A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma
21. SO-26 Clinical efficacy of combined BRAF, MEK, and PD-1 inhibition in BRAFV600E colorectal cancer patients
22. Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer
23. Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer
24. Prognostic significance of immune cell populations identified by machine learning in colorectal cancer using routine hematoxylin and eosin–stained sections
25. An integrated analysis of lymphocytic reaction, tumour molecular characteristics and patient survival in colorectal cancer
26. Metabolic profiling of formalin-fixed paraffin-embedded tissues discriminates normal colon from colorectal cancer
27. Smoking status at diagnosis and colorectal cancer prognosis according to tumor lymphocytic reaction
28. Association of autophagy status with amount of Fusobacterium nucleatum in colorectal cancer
29. Tumour budding, poorly differentiated clusters, and T-cell response in colorectal cancer
30. Phase II study of capecitabine, oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC): 3580
31. Insulin-like growth factor-I (IGF-1), IGF binding protein-3 (IGFBP-3), and outcome in metastatic colorectal cancer (CRC): Results from Intergroup Trial N9741: 3521
32. Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)
33. Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC)
34. 458PD - Causal modeling of CALGB/SWOG 80405 (Alliance) identifies primary (1°) side-related angiogenic drivers of metastatic colorectal cancer (mCRC)
35. The Idea (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: a Prospective Pooled Non-Inferiority Analysis of > 11,500 Patients from 6 Phase III Trials of Adjuvant Therapy Duration with Folfox (Folfox4 or Mfolfox6) or Xelox (3 Vs. 6 Months) for Stage III Colon Cancer
36. Response
37. Chemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer
38. 139P - Levels of endogenous anti-beta-glucan IgG antibodies (ABA) predict clinical outcomes for imprime PGG: Evidence from phase 3 PRIMUS study in patients (pts) with metastatic colorectal cancer (mCRC)
39. Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology
40. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors
41. Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803
42. A comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients.
43. Abstract PD08-09: Impact of a Telephone-Based Exercise Intervention on Physical Activity Behaviors and Fitness in a Cooperative Group Setting
44. Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer
45. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) in previously treated metastatic colorectal cancer (mCRC).
46. Phase I/II study of everolimus in patients with advanced hepatocellular carcinoma (HCC).
47. Erratum: Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
48. Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer
49. Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
50. Phase II and fluorodeoxyglucose positron emission tomography (FDG-PET) study in patients with advanced biliary tract cancers (BTCs) receiving bevacizumab (B) in combination with gemcitabine (GEM) and oxaliplatin (OX)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.